Trientine reduces BACE1 activity and mitigates amyloidosis via the AGE/RAGE/NF-κB pathway in a transgenic mouse model of alzheimer's disease

Antioxidants and Redox Signaling

Volumn 19, Issue 17, 2013, Pages 2024-2039

  Wang, Chun Yan ^a,b   Xie, Jing Wei ^a   Xu, Ye ^b   Wang, Tao ^a   Cai, Jian Hui ^b   Wang, Xu ^c   Zhao, Bao Lu ^d   An, Li ^a   Wang, Zhan You ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b JILIN MEDICAL COLLEGE   (China)

^c LIAONING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^d INSTITUTE OF BIOPHYSICS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN; BETA SECRETASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRIENTINE;

ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; FEMALE; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CLEAVAGE; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; SYNAPSE; TRANSGENIC MOUSE; TREATMENT DURATION; TREATMENT RESPONSE;

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; AMYLOIDOSIS; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; CELL LINE, TUMOR; CEREBRAL CORTEX; CERULOPLASMIN; CHELATING AGENTS; COPPER; DOWN-REGULATION; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MALONDIALDEHYDE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NF-KAPPA B; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION; SUPEROXIDE DISMUTASE; TRIENTINE;

EID: 84889763950     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2012.5158     Document Type: Article

References (79)

1. Angeletti B, Waldron KJ, Freeman KB, Bawagan H, Hussain I, Miller CC, Lau KF, Tennant ME, Dennison C, Robinson NJ, and Dingwall C. BACE1 cytoplasmic domain interacts with the copper chaperone for superoxide dismutase-1 and binds copper. J Biol Chem 280: 17930-17937, 2005.
2. Arancio O, Zhang HP, Chen X, Lin C, Trinchese F, Puzzo D, Liu S, Hegde A, Yan SF, Stern A, Luddy JS, Lue LF, Walker DG, Roher A, Buttini M, Mucke L, Li W, Schmidt AM, Kindy M, Hyslop PA, Stern DM, and Du Yan SS. RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J 23: 4096-4105, 2004.
3. Ascolani A, Balestrieri E, Minutolo A, Mosti S, Spalletta G, Bramanti P, Mastino A, Caltagirone C, and Macchi B. Dysregulated NF-kappaB pathway in peripheral mononuclear cells of Alzheimer's disease patients. Curr Alzheimer Res 9: 128-137, 2012.
4. Atwood CS, Perry G, Zeng H, Kato Y, Jones WD, Ling KQ, Huang X, Moir RD, Wang D, Sayre LM, Smith MA, Chen SG, and Bush AI. Copper mediates dityrosine cross-linking of Alzheimer's amyloid-beta. Biochemistry 43: 560-568, 2004.
5. Baynes JW and Murray DB. The metal chelators, trientine and citrate, inhibit the development of cardiac pathology in the Zucker diabetic rat. Exp Diabetes Res 2009: 696378, 2009.
6. Bourne KZ, Ferrari DC, Lange-Dohna C, Rossner S, Wood TG, and Perez-Polo Jr. Differential regulation of BACE1 promoter activity by nuclear factor-kappaB in neurons and glia upon exposure to beta-amyloid peptides. J Neurosci Res 85: 1194-1204, 2007.
7. Bucciarelli LG, Wendt T, Rong L, Lalla E, Hofmann MA, Goova MT, Taguchi A, Yan SF, Yan SD, Stern DM, and Schmidt AM. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci 59: 1117-1128, 2002.
8. Buggia-Prevot V, Sevalle J, Rossner S, and Checler F. NFkappaB-dependent control of BACE1 promoter transactivation by Abeta42. J Biol Chem 283: 10037-10047, 2008.
9. Bush AI. Copper, zinc, and the metallobiology of Alzheimer disease. Alzheimer Dis Assoc Disord 17: 147-150, 2003.
10. Bush AI, Pettingell WH, Jr., Paradis MD, and Tanzi RE. Modulation of A beta adhesiveness and secretase site cleavage by zinc. J Biol Chem 269: 12152-12158, 1994.
11. Butterfield DA and Lauderback CM. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptideassociated free radical oxidative stress. Free Radic Biol Med 32: 1050-1060, 2002.
12. Calabrese V, Cornelius C, Cuzzocrea S, Iavicoli I, Rizzarelli E, and Calabrese EJ. Hormesis, cellular stress response and vitagenes as critical determinants in aging and longevity. Mol Aspects Med 32: 279-304, 2011.
13. Calabrese V, Cornelius C, Dinkova-Kostova AT, Calabrese EJ, and Mattson MP. Cellular stress responses, the hormesis paradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders. Antioxid Redox Signal 13: 1763-1811, 2010.
14. Calabrese V, Cornelius C, Dinkova-Kostova AT, Iavicoli I, Di Paola R, Koverech A, Cuzzocrea S, Rizzarelli E, and Calabrese EJ. Cellular stress responses, hormetic phytochemicals and vitagenes in aging and longevity. Biochim Biophys Acta 1822: 753-783, 2012.
15. Calabrese V, Mancuso C, Calvani M, Rizzarelli E, Butterfield DA, and Stella AM. Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nat Rev Neurosci 8: 766-775, 2007.
16. Cameron NE and Cotter MA. Neurovascular dysfunction in diabetic rats. Potential contribution of autoxidation and free radicals examined using transition metal chelating agents. J Clin Invest 96: 1159-1163, 1995.
17. Carubelli R, Schneider JE, Jr., Pye QN, and Floyd RA. Cytotoxic effects of autoxidative glycation. Free Radic Biol Med 18: 265-269, 1995.
18. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim Y, Huang X, Goldstein LE, Moir RD, Lim JT, Beyreuther K, Zheng H, Tanzi RE, Masters CL, and Bush AI. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30: 665-676, 2001.
19. Cherny RA, Barnham KJ, Lynch T, Volitakis I, Li QX, McLean CA, Multhaup G, Beyreuther K, Tanzi RE, Masters CL, and Bush AI. Chelation and intercalation: complementary properties in a compound for the treatment of Alzheimer's disease. J Struct Biol 130: 209-216, 2000.
20. Chiurchiu V and Maccarrone M. Chronic inflammatory disorders and their redox control: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal 15: 2605-2641, 2011.
21. Cho HJ, Son SM, Jin SM, Hong HS, Shin DH, Kim SJ, Huh K, and Mook-Jung I. RAGE regulates BACE1 and Abeta generation via NFAT1 activation in Alzheimer's disease animal model. FASEB J 23: 2639-2649, 2009.
22. Cooper GJ. Therapeutic potential of copper chelation with triethylenetetramine in managing diabetes mellitus and Alzheimer's disease. Drugs 71: 1281-1320, 2011.
23. Cooper GJ, Phillips AR, Choong SY, Leonard BL, Crossman DJ, Brunton DH, Saafi L, Dissanayake AM, Cowan BR, Young AA, Occleshaw CJ, Chan YK, Leahy FE, Keogh GF, Gamble GD, Allen GR, Pope AJ, Boyd PD, Poppitt SD, Borg TK, Doughty RN, and Baker Jr. Regeneration of the heart in diabetes by selective copper chelation. Diabetes 53: 2501-2508, 2004.
24. Cooper GJ, Young AA, Gamble GD, Occleshaw CJ, Dissanayake AM, Cowan BR, Brunton DH, Baker JR, Phillips AR, Frampton CM, Poppitt SD, and Doughty RN. A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebocontrolled study. Diabetologia 52: 715-722, 2009.
25. Cui Z, Lockman PR, Atwood CS, Hsu CH, Gupte A, Allen DD, and Mumper RJ. Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases. Eur J Pharm Biopharm 59: 263-272, 2005.
26. Danscher G. Autometallography. A new technique for light and electron microscopic visualization of metals in biological tissues (gold, silver, metal sulphides and metal selenides). Histochemistry 81: 331-335, 1984.
27. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, and Zlokovic B. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9: 907-913, 2003.
28. Deane R, Wu Z, and Zlokovic BV. RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke 35: 2628-2631, 2004.
29. Dong J, Atwood CS, Anderson VE, Siedlak SL, Smith MA, Perry G, and Carey PR. Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence. Biochemistry 42: 2768-2773, 2003.
30. Dong J, Canfield JM, Mehta AK, Shokes JE, Tian B, Childers WS, Simmons JA, Mao Z, Scott RA, Warncke K, and Lynn DG. Engineering metal ion coordination to regulate amyloid fibril assembly and toxicity. Proc Natl Acad Sci U S A 104: 13313-13318, 2007.
31. Eskici G and Axelsen PH. Copper and oxidative stress in the pathogenesis of Alzheimer's disease. Biochemistry 51: 6289-6311, 2012.
32. Frederickson CJ, Kasarskis EJ, Ringo D, and Frederickson RE. A quinoline fluorescence method for visualizing and assaying the histochemically reactive zinc (bouton zinc) in the brain. J Neurosci Methods 20: 91-103, 1987.
33. Frommer DJ. Defective biliary excretion of copper in Wilson's disease. Gut 15: 125-129, 1974.
34. Granic I, Dolga AM, Nijholt IM, van Dijk G, and Eisel UL. Inflammation and NF-kappaB in Alzheimer's disease and diabetes. J Alzheimers Dis 16: 809-821, 2009.
35. Guglielmotto M, Aragno M, Tamagno E, Vercellinatto I, Visentin S, Medana C, Catalano MG, Smith MA, Perry G, Danni O, Boccuzzi G, and Tabaton M. AGEs/RAGE complex upregulates BACE1 via NF-kappaB pathway activation. Neurobiol Aging 33: 196 e13-196 e 27, 2012.
36. Hardy J and Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356, 2002.
37. Hardy JA and Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 256: 184-185, 1992.
38. Hayden MS and Ghosh S. Signaling to NF-kappaB. Genes Dev 18: 2195-2224, 2004.
39. Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC, and Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53: 474-481, 2004.
40. Kaltschmidt B, Uherek M, Volk B, Baeuerle PA, and Kaltschmidt C. Transcription factor NF-kappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc Natl Acad Sci U S A 94: 2642-2647, 1997.
41. Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, and Schmidt AM. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogenactivated protein kinase pathway regulated by oxidant stress. J Biol Chem 272: 17810-17814, 1997.
42. Lee JY, Mook-Jung I, and Koh JY. Histochemically reactive zinc in plaques of the Swedish mutant beta-amyloid precursor protein transgenic mice. J Neurosci 19: RC10, 1999.
43. Liu J, Guo L, Yin F, Zheng X, Chen G, and Wang Y. Characterization and antitumor activity of triethylene tetramine, a novel telomerase inhibitor. Biomed Pharmacother 62: 480-485, 2008.
44. Loske C, Gerdemann A, Schepl W, Wycislo M, Schinzel R, Palm D, Riederer P, and Munch G. Transition metal-mediated glycoxidation accelerates cross-linking of beta-amyloid peptide. Eur J Biochem 267: 4171-4178, 2000.
45. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, and Markesbery WR. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 158: 47-52, 1998.
46. Luchsinger JA, Tang MX, Stern Y, Shea S, and Mayeux R. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 154: 635-641, 2001.
47. Lue LF, Walker DG, Brachova L, Beach TG, Rogers J, Schmidt AM, Stern DM, and Yan SD. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp Neurol 171: 29-45, 2001.
48. Lutsenko S, LeShane ES, and Shinde U. Biochemical basis of regulation of human copper-transporting ATPases. Arch Biochem Biophys 463: 134-148, 2007.
49. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 23: 134-147, 1997.
50. Maynard CJ, Bush AI, Masters CL, Cappai R, and Li QX. Metals and amyloid-beta in Alzheimer's disease. Int J Exp Pathol 86: 147-159, 2005.
51. Maynard CJ, Cappai R, Volitakis I, Cherny RA, Masters CL, Li QX, and Bush AI. Gender and genetic background effects on brain metal levels in APP transgenic and normal mice: implications for Alzheimer beta-amyloid pathology. J Inorg Biochem 100: 952-962, 2006.
52. Miller MC, Tavares R, Johanson CE, Hovanesian V, Donahue JE, Gonzalez L, Silverberg GD, and Stopa EG. Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease. Brain Res 1230: 273-280, 2008.
53. Moriguchi M, Nakajima T, Kimura H, Watanabe T, Takashima H, Mitsumoto Y, Katagishi T, Okanoue T, and Kagawa K. The copper chelator trientine has an antiangiogenic effect against hepatocellular carcinoma, possibly through inhibition of interleukin-8 production. Int J Cancer 102: 445-452, 2002.
54. Munch G, Mayer S, Michaelis J, Hipkiss AR, Riederer P, Muller R, Neumann A, Schinzel R, and Cunningham AM. Influence of advanced glycation end-products and AGEinhibitors on nucleation-dependent polymerization of beta-amyloid peptide. Biochim Biophys Acta 1360: 17-29, 1997.
55. Nakamura J, Hamada Y, Chaya S, Nakashima E, Naruse K, Kato K, Yasuda Y, Kamiya H, Sakakibara F, Koh N, and Hotta N. Transition metals and polyol pathway in the development of diabetic neuropathy in rats. Diabetes Metab Res Rev 18: 395-402, 2002.
56. O'Reilly S, Weber PM, Oswald M, and Shipley L. Abnormalities of the physiology of copper in Wilson's disease. The excretion of copper. Arch Neurol 25: 28-32, 1971.
57. Opazo C, Huang X, Cherny RA, Moir RD, Roher AE, White AR, Cappai R, Masters CL, Tanzi RE, Inestrosa NC, and Bush AI. Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J Biol Chem 277: 40302-40308, 2002.
58. Ortwerth BJ, James H, Simpson G, and Linetsky M. The generation of superoxide anions in glycation reactions with sugars, osones, and 3-deoxyosones. Biochem Biophys Res Commun 245: 161-165, 1998.
59. Quinn JF, Harris CJ, Cobb KE, Domes C, Ralle M, Brewer G, and Wadsworth TL. A copper-lowering strategy attenuates amyloid pathology in a transgenic mouse model of Alzheimer's disease. J Alzheimers Dis 21: 903-914, 2010.
60. Reddy PH. Amyloid precursor protein-mediated free radicals and oxidative damage: implications for the development and progression of Alzheimer's disease. J Neurochem 96: 1-13, 2006.
61. Religa D, Strozyk D, Cherny RA, Volitakis I, Haroutunian V, Winblad B, Naslund J, and Bush AI. Elevated cortical zinc in Alzheimer disease. Neurology 67: 69-75, 2006.
62. Salkovic-Petrisic M and Hoyer S. Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: an experimental approach. J Neural Transm Suppl 72: 217-233, 2007.
63. Schmidt AM, Yan SD, Yan SF, and Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 1498: 99-111, 2000.
64. Schmidt AM, Yan SD, Yan SF, and Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 108: 949-955, 2001.
65. Schonberger SJ, Edgar PF, Kydd R, Faull RL, and Cooper GJ. Proteomic analysis of the brain in Alzheimer's disease: molecular phenotype of a complex disease process. Proteomics 1: 1519-1528, 2001.
66. Schosinsky KH, Lehmann HP, and Beeler MF. Measurement of ceruloplasmin from its oxidase activity in serum by use of o-dianisidine dihydrochloride. Clin Chem 20: 1556-1563, 1974.
67. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 298: 789-791, 2002.
68. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81: 741-766, 2001.
69. Selkoe DJ. Amyloid beta protein precursor and the pathogenesis of Alzheimer's disease. Cell 58: 611-612, 1989.
70. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, and Selkoe DJ. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14: 837-842, 2008.
71. Shoji M, Golde TE, Ghiso J, Cheung TT, Estus S, Shaffer LM, Cai XD, McKay DM, Tintner R, Frangione B, et al. Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 258: 126-129, 1992.
72. Terai K, Matsuo A, and McGeer PL. Enhancement of immunoreactivity for NF-kappa B in the hippocampal formation and cerebral cortex of Alzheimer's disease. Brain Res 735: 159-168, 1996.
73. Trojanowski JQ and Lee VM. Phosphorylation of paired helical filament tau in Alzheimer's disease neurofibrillary lesions: focusing on phosphatases. FASEB J 9: 1570-1576, 1995.
74. Vassar R, Kovacs DM, Yan R, and Wong PC. The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential. J Neurosci 29: 12787-12794, 2009.
75. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, and Selkoe DJ. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416: 535-539, 2002.
76. Walshe JM. Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride. Lancet 1: 643-647, 1982.
77. Wang CY, Zheng W, Wang T, Xie JW, Wang SL, Zhao BL, Teng WP, and Wang ZY. Huperzine A activates Wnt/ beta-catenin signaling and enhances the nonamyloidogenic pathway in an Alzheimer transgenic mouse model. Neuropsychopharmacology 36: 1073-1089, 2011.
78. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, and Schmidt AM. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382: 685-691, 1996.
79. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, Pinsky D, and Stern D. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269: 9889-9897, 1994.